These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 1322690

  • 1. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
    Tazzari PL, Bolognesi A, de Totero D, Falini B, Lemoli RM, Soria MR, Pileri S, Gobbi M, Stein H, Flenghi L.
    Br J Haematol; 1992 Jun; 81(2):203-11. PubMed ID: 1322690
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
    Terenzi A, Bolognesi A, Pasqualucci L, Flenghi L, Pileri S, Stein H, Kadin M, Bigerna B, Polito L, Tazzari PL, Martelli MF, Stirpe F, Falini B.
    Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.
    Pasqualucci L, Wasik M, Teicher BA, Flenghi L, Bolognesi A, Stirpe F, Polito L, Falini B, Kadin ME.
    Blood; 1995 Apr 15; 85(8):2139-46. PubMed ID: 7718885
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE, Brown AN, Bremner JA, Foxwell BM, Stirpe F.
    J Natl Cancer Inst; 1985 Jul 15; 75(1):151-9. PubMed ID: 3859688
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
    Engert A, Martin G, Pfreundschuh M, Amlot P, Hsu SM, Diehl V, Thorpe P.
    Cancer Res; 1990 May 15; 50(10):2929-35. PubMed ID: 1692251
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.
    Tazzari PL, Zhang S, Chen Q, Sforzini S, Bolognesi A, Stirpe F, Xie H, Moretta A, Ferrini S.
    Br J Cancer; 1993 Jun 15; 67(6):1248-53. PubMed ID: 8512810
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
    Bolognesi A, Tazzari PL, Olivieri F, Polito L, Lemoli R, Terenzi A, Pasqualucci L, Falini B, Stirpe F.
    Br J Haematol; 1998 Apr 15; 101(1):179-88. PubMed ID: 9576199
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
    Flavell DJ, Flavell SU, Boehm DA, Emery L, Noss A, Ling NR, Richardson PR, Hardie D, Wright DH.
    Br J Cancer; 1995 Dec 15; 72(6):1373-9. PubMed ID: 8519647
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice.
    Morland BJ, Barley J, Boehm D, Flavell SU, Ghaleb N, Kohler JA, Okayama K, Wilkins B, Flavell DJ.
    Br J Cancer; 1994 Feb 15; 69(2):279-85. PubMed ID: 7507691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.